Biotechnology, Venture Capital, Oncology · medium ·
DNA Vaccine Investment Faces a Delivery Solution Shortage
Investment in DNA vaccine platforms is becoming increasingly selective, focusing on companies and projects that can demonstrate de-risked delivery solutions and strong T-cell-inducing indications. This creates a critical shortage of validated delivery technologies, making them a key bottleneck for attracting capital.